Novel mutations in neuroendocrine carcinoma of the breast: Possible therapeutic targets

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 2, 2015, Pages 97-103

  Ang, Daphne ^a   Ballard, Morgan ^a,c   Beadling, Carol ^b   Warrick, Andrea ^b   Schilling, Amy ^b   O'Gara, Rebecca ^b   Pukay, Marina ^b   Neff, Tanaya L ^b   West, Robert B ^c   Corless, Christopher L ^a,b   Troxell, Megan L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FGFR1; FGFR4; HRAS; KDR; neuroendocrine breast carcinoma; PIK3CA

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; FGFR1 PROTEIN, HUMAN; HRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2;

ANGIOSARCOMA; ARTICLE; BREAST CARCINOMA; BREAST NEUROENDOCRINE CARCINOMA; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; METASTASIS; NEXT GENERATION SEQUENCING; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR GENE; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES;

BREAST NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84923829774     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3182a40fd1     Document Type: Article

References (47)

1. Ellis IO, Schnitt S, Sastre-Garau X, et al. Invasive breast carcinomas: neuroendocrine tumors. In: Tavassoli FA, Devilee P, eds. Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:32-34
2. Bussolati G, Badve S. Carcinomas with neuroendocrine features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds. WHO Classification of Tumours of the Breast. Lyon, France: IARC Press; 2012:62-63
3. Righi L, Sapino A, Marchio C, et al. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Sem Diagn Pathol. 2010;27:69-76
4. Tang F, Wei B, Tian Z, et al. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011;59:106-115
5. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6: 718-730
6. Makretsov N, Gilks B, Coldman AJ, et al. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001-1008
7. Ló pez-Bonet E, Alonso-Ruano M, Barraza G, et al. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369-1374
8. Upalakalin JN, Collins LC, Tawa N, et al. Carcinoid tumors in the breast. Am J Surg. 2006;191:799-805
9. Alkaied H, Harris K, Azab B, et al. Primary neuroendocrine breast cancer, how much do we know so far?Med Oncol. 2012;29:2613-2618
10. Toyoshima S. Mammary carcinoma with argyrophil cells. Cancer. 1983;52:2129-2138
11. David O, Bhattacharjee M. Diffuse neuroendocrine differentiation in a morphologically composite mammary infiltrating ductal carcinoma: a case report and review of the literature. Arch Pathol Lab Med. 2003;127:e131-e134
12. Wei B, Ding T, Xing Y, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010;116:4463-4473
13. Zhang Y, Chen Z, Bao Y, et al. Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma. 2013;60:215-222
14. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-150
15. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 2009;22: 1401-1414
16. Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 2010;222:282-298
17. Webster JA, Beck AH, Sharma M, et al. Variations in stromal signatures in breast and colorectal cancer metastases. J. Pathol. 2010;222:158-165
18. Troxell ML, Levine J, Beadling C, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol. 2010;23:27-37
19. Kehr EL, Jorns JM, Ang D, et al. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol. 2012;43:2207-2212
20. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry: evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn. 2011;13: 504-513
21. Troxell ML, Brunner AL, Neff T, et al. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Mod Pathol. 2012;25:930-937
22. Ang D, O'Gara R, Schilling A, et al. Novel method for PIK3CA mutation analysis: locked nucleic acid-PCR sequencing. J Mol Diagn. 2013;15:312-318
23. Beadling C, Neff TL, Heinrich MC, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 2013;15:171-176
24. Papotti M, Macri L, Finzi G, et al. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol. 1989;6:174-188
25. Troxell ML. PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies. J Clinic Exp Pathol. 2012;S1:002. doi:10.4172/2161-0681.S1-002. Available at: http://www.omicsonline.org/searchresult.php
26. Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013;39:313-320
27. Tenhagen M, van Diest PJ, Ivanovi A, et al. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer. 2012;19: R115-R129
28. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116-129
29. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25: 581-593
30. Taylor JG VI, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119: 3395-3407
31. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2011;18: 748-757
32. Jacobson-Dunlop E, Mansoor A, Corless CL. FBXW7 mutations in a subset of embryonal rhabdomyosarcoma. Mod Pathol. 2012; 25(S2):14A
33. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005;37:590-592
34. Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693-3702
35. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2013. doi: 10.1002/med.21288. [Epub ahead of print]
36. Antonescu CR, Yodhida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175-7179
37. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075
38. Glubb DM, Cerri E, Giese A, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011;17:5257-5267
39. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457-2467
40. Loyo M, Li RJ, Bettegowda C, et al. Lessons learned from nextgeneration sequencing in head and neck cancer. Head Neck. 2013;35:454-463
41. van Engen-van Grunsven AC, van Dijk MC, et al. HRAS-mutated Spitz tumors: a subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010;34:1436-1441
42. Tong L, Yang X-X, Min-Feng Liu M-F, et al. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev. 2012;13:5599-5603
43. Martin V, Botta F, Zanellato E, et al. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol. 2012;27: 785-792
44. Esposito N, Nikiforova M, Nikiforov Y, et al. Mutational profile of RAS and BRAF genes in papillary lesions of the breast: identification of a common HRAS mutation in intracystic papillary carcinoma. Mod Pathol. 2008;21:47A
45. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70
46. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466: 869-873
47. Hollestelle A, Nagel JHA, Smid M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121:53-64.